About Nectar Life Sciences Limited
Data last updated:
Nectar Life Sciences Limited is a public limited company based in Derabassi, Punjab, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 27 June 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L24232PB1995PLC016664. Its GSTIN is 03AABCS6468G1ZD (Punjab). The company holds 18 GST registrations, of which 5 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532649 and NSE: NECLIFE.
The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹22.43 Cr. It was formerly known as Surya Medicare Limited. It is led by directors including Sanjiv Goyal (Managing Director) and Sushil Kapoor (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507.
The net worth stands at ₹582.3 Cr (down 39.1% YoY). Total assets are valued at ₹595.56 Cr (down 61.5% YoY).
The company has about 1,814 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Nectar Lifesciences. As per MCA filings, the company has open charges of ₹60.47 Lakh and satisfied charges of ₹6,249.44 Cr on record. Court records list 436 cases involving the company, including 347 filed by the company and 89 filed against it; 34 cases are pending. The company has 66 deals on record (61 market trades, 3 funding rounds, 1 secondary share transfer), with disclosed funding of ₹201.41 Cr; the latest was in December 2025. Its 10 peer companies in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Leeford Healthcare Limited with revenue of ₹1,730.47 Cr. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 185 overdue payments to 21 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website neclife.com.
Company details
CIN history
Nectar Life Sciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24232PB1995PLC016664, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232PB1995PLC016664 | Current |
| U24232PB1995PLC016664 | Previous |
| L21000PB1995PLC016664 | Previous |
Contact details
Nectar Life Sciences Limited's registered office is in Derabassi, Punjab. Its website is neclife.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressShop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507
- IndustryPharma, Drug Formulation & Development, API Manufacturers
To see the full contact details of Nectar Life Sciences Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Nectar Life Sciences operates one associated brand: Nectar Lifesciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Cephalosporin APIs and generic formulations are manufactured. | neclife.com |
Business activity
The main business activity of Nectar Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Nectar Life Sciences Limited, buy the company report.
Financials of Nectar Life Sciences Limited
FY 2025-26 filings availableNectar Life Sciences Limited reported revenue of ₹- (down 100% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 1,670 | 1,684 | 1,524 | 1,669 | 1,543 | 2,366 |
| Revenue growth | -100.0% | -0.8% | +10.5% | -8.7% | +8.1% | -34.8% | - |
| EBITDA | (296) | (29.56) | 152 | 53.01 | 159 | 83.72 | 220 |
| EBITDA margin | - | -1.8% | +9.0% | +3.5% | +9.5% | +5.4% | +9.3% |
| Profit before tax | (323) | (162) | 18.27 | (42.42) | 34.07 | (84.78) | 37.46 |
| Net profit | (241) | (114) | 4.88 | (64.69) | 18.12 | (47.87) | 31.56 |
| Net profit margin | - | -6.8% | +0.3% | -4.3% | +1.1% | -3.1% | +1.3% |
| EPS (₹) | (15.08) | (5.07) | 0.22 | (1.08) | 1.12 | (3.27) | 1.42 |
| Balance sheet | |||||||
| Total assets | 596 | 1,548 | 1,713 | 1,826 | 1,956 | 1,976 | 1,926 |
| Net worth | 582 | 956 | 1,069 | 1,065 | 1,088 | 1,062 | 1,136 |
| Total debt | 0.00 | 582 | 636 | 754 | 860 | 903 | 779 |
| Cash & bank | 112 | 19.22 | 19.81 | 17.58 | 17.81 | 25.54 | 21.29 |
| Net working capital | 214 | 737 | 806 | 867 | 919 | 826 | 1,024 |
| Cash flow | |||||||
| Cash from operations | (349) | 169 | 225 | 134 | 95.01 | 21.38 | 285 |
| Cash from investing | 1,208 | (41.93) | (17.03) | 51.70 | 16.64 | (28.62) | (33.13) |
| Cash from financing | (767) | (128) | (205) | (186) | (119) | 11.49 | (252) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.44 | 1.29 | 0.00 | 0.71 | 5.24 | 0.01 | 0.01 | 5.74 |
| Revenue growth (YoY) | -91.6% | - | -100.0% | -87.6% | -98.5% | - | - | - |
| Other income | 3.24 | 6.29 | 35.46 | 0.03 | 0.32 | 0.18 | 8.08 | 6.52 |
| EBITDA | (27.27) | (87.95) | (1.92) | (176) | (63.39) | (130) | (0.04) | (0.58) |
| EBITDA margin | - | - | - | - | -1212.0% | - | - | -10.1% |
| Depreciation | 0.11 | 0.08 | 0.06 | 0.11 | 0.53 | 0.30 | 0.07 | 0.45 |
| Interest | 0.16 | 5.90 | 30.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (24.30) | (87.64) | 3.26 | (176) | (63.60) | (130) | 7.97 | 5.49 |
| Tax | (8.90) | (19.72) | (11.02) | 0.16 | (0.37) | (0.06) | 0.12 | (0.12) |
| Net profit | (15.40) | (67.92) | 14.28 | (176) | (63.23) | (130) | 7.85 | 5.61 |
| EPS (₹) | (0.79) | (3.38) | 0.64 | (7.85) | (2.82) | (5.80) | 0.35 | 0.25 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 0.00 | 1,684 | 1,524 | 1,668 | 1,542 | 2,363 |
| Revenue growth | - | -100.0% | +10.5% | -8.7% | +8.2% | -34.8% | - |
| EBITDA | (296) | (115) | 152 | 54.73 | 159 | 83.82 | 218 |
| EBITDA margin | - | - | +9.0% | +3.6% | +9.5% | +5.4% | +9.2% |
| Profit before tax | (323) | (113) | 18.28 | (40.69) | 34.35 | (84.67) | 35.75 |
| Net profit | (241) | (114) | 4.83 | (62.96) | 15.91 | (47.76) | 29.85 |
| Net profit margin | - | - | +0.3% | -4.1% | +1.0% | -3.1% | +1.3% |
| EPS (₹) | (15.08) | (5.07) | 0.22 | (1.00) | 1.13 | (3.26) | 1.34 |
| Balance sheet | |||||||
| Total assets | 586 | 1,548 | 1,713 | 1,826 | 1,955 | 1,975 | 1,925 |
| Net worth | 582 | 956 | 1,069 | 1,065 | 1,087 | 1,061 | 1,135 |
| Total debt | 0.00 | 582 | 636 | 754 | 860 | 903 | 779 |
| Cash & bank | 108 | 19.22 | 19.80 | 17.57 | 17.74 | 25.43 | 21.23 |
| Net working capital | 211 | 737 | 806 | 867 | 918 | 825 | 1,023 |
| Cash flow | |||||||
| Cash from operations | (417) | 169 | 225 | 133 | 95.04 | 21.33 | 286 |
| Cash from investing | 1,205 | (41.93) | (17.03) | 52.03 | 16.64 | (28.62) | (33.14) |
| Cash from financing | (699) | (128) | (205) | (186) | (119) | 11.49 | (252) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.44 | 1.29 | 0.00 | 5.71 | 5.24 | 0.01 | 455 | 5.74 |
| Revenue growth (YoY) | -91.6% | - | -100.0% | -0.5% | -98.5% | - | - | - |
| Other income | 6.17 | 6.29 | 35.46 | 0.03 | 0.32 | 0.18 | 0.57 | 6.52 |
| Total expenses | 27.68 | 89.23 | 1.92 | 182 | 68.63 | 130 | 410 | 6.32 |
| EBITDA | (27.24) | (87.94) | (1.92) | (176) | (63.39) | (130) | 44.71 | (0.58) |
| EBITDA margin | - | - | - | -3520.2% | -1212.0% | - | +9.8% | -10.1% |
| Depreciation | 0.11 | 0.08 | 0.06 | 0.20 | 0.53 | 0.30 | 15.61 | 0.45 |
| Interest | 0.16 | 5.90 | 30.22 | 0.00 | 0.00 | 0.00 | 17.12 | 0.00 |
| Profit before tax | (21.34) | (87.63) | 3.26 | (176) | (63.60) | (130) | 12.55 | 5.49 |
| Tax | (8.20) | (19.71) | (11.02) | (0.18) | (0.37) | (0.06) | 4.71 | (0.12) |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.44 | 1.29 | 0.00 | 0.71 | 5.24 | 0.01 | 0.01 | 5.74 |
| Revenue growth (YoY) | -91.6% | - | -100.0% | -87.6% | -98.5% | - | - | - |
| Other income | 3.24 | 6.29 | 35.46 | 0.03 | 0.32 | 0.18 | 8.08 | 6.52 |
| EBITDA | (27.27) | (87.95) | (1.92) | (176) | (63.39) | (130) | (0.04) | (0.58) |
| EBITDA margin | - | - | - | - | -1212.0% | - | - | -10.1% |
| Depreciation | 0.11 | 0.08 | 0.06 | 0.11 | 0.53 | 0.30 | 0.07 | 0.45 |
| Interest | 0.16 | 5.90 | 30.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (24.30) | (87.64) | 3.26 | (176) | (63.60) | (130) | 7.97 | 5.49 |
| Tax | (8.90) | (19.72) | (11.02) | 0.16 | (0.37) | (0.06) | 0.12 | (0.12) |
| Net profit | (15.40) | (67.92) | 14.28 | (176) | (63.23) | (130) | 7.85 | 5.61 |
| EPS (₹) | (0.79) | (3.38) | 0.64 | (7.85) | (2.82) | (5.80) | 0.35 | 0.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1,670 | 1,684 | 1,524 | 1,669 | 1,543 | 2,366 |
| Revenue growth | -100.0% | -0.8% | +10.5% | -8.7% | +8.1% | -34.8% | - |
| Other income | 9.29 | 4.99 | 14.58 | 43.18 | 11.32 | 3.79 | 4.36 |
| Total expenses | 296 | 1,700 | 1,533 | 1,471 | 1,510 | 1,460 | 2,147 |
| Employee cost | 0.90 | 93.61 | 81.71 | 75.13 | 71.91 | 70.59 | 78.19 |
| EBITDA | (296) | (29.56) | 152 | 53.01 | 159 | 83.72 | 220 |
| EBITDA margin | - | -1.8% | +9.0% | +3.5% | +9.5% | +5.4% | +9.3% |
| Depreciation | 0.34 | 62.39 | 60.72 | 59.12 | 56.97 | 60.25 | 60.77 |
| Interest | 36.13 | 74.58 | 87.14 | 79.49 | 78.81 | 112 | 126 |
| Profit before tax | (323) | (162) | 18.27 | (42.42) | 34.07 | (84.78) | 37.46 |
| Tax | (30.53) | (47.85) | 13.28 | (18.24) | 9.03 | (11.50) | 5.68 |
| Net profit | (241) | (114) | 4.88 | (64.69) | 18.12 | (47.87) | 31.56 |
| Net profit margin | - | -6.8% | +0.3% | -4.3% | +1.1% | -3.1% | +1.3% |
| EPS (₹) | (15.08) | (5.07) | 0.22 | (1.08) | 1.12 | (3.27) | 1.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 19.43 | 22.43 | 22.43 | 22.43 | 22.43 | 22.43 | 22.43 |
| Reserves & surplus | 563 | 934 | 1,047 | 1,042 | 1,065 | 1,040 | 1,114 |
| Shareholders' funds (net worth) | 582 | 956 | 1,069 | 1,065 | 1,088 | 1,062 | 1,136 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 487 | 540 | 672 | 784 | 840 | 760 |
| Unsecured loans | 0.00 | 94.68 | 96.01 | 81.45 | 76.08 | 63.17 | 18.45 |
| Total debt | 0.00 | 582 | 636 | 754 | 860 | 903 | 779 |
| Total liabilities | 596 | 1,548 | 1,713 | 1,826 | 1,956 | 1,976 | 1,926 |
| Assets | |||||||
| Gross block | 107 | 1,652 | 1,599 | 1,558 | 1,563 | 1,556 | 1,509 |
| Net block | 105 | 633 | 643 | 662 | 723 | 772 | 785 |
| Capital work in progress | 0.00 | 56.73 | 65.75 | 77.78 | 85.10 | 98.63 | 115 |
| Investments | 13.21 | 0.77 | 0.73 | 0.55 | 0.70 | 0.69 | 0.40 |
| Inventories | 0.30 | 690 | 709 | 673 | 660 | 588 | 978 |
| Sundry debtors | 0.00 | 345 | 379 | 280 | 447 | 375 | 396 |
| Cash & bank balances | 112 | 19.22 | 19.81 | 17.58 | 17.81 | 25.54 | 21.29 |
| Loans & advances | 128 | 182 | 175 | 261 | 230 | 250 | 220 |
| Total current assets | 240 | 1,237 | 1,283 | 1,231 | 1,354 | 1,238 | 1,615 |
| Total current liabilities | 26.06 | 500 | 478 | 364 | 435 | 412 | 591 |
| Net working capital | 214 | 737 | 806 | 867 | 919 | 826 | 1,024 |
| Total assets | 596 | 1,548 | 1,713 | 1,826 | 1,956 | 1,976 | 1,926 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 19.22 | 19.81 | 17.58 | 17.81 | 25.54 | 21.29 | 21.33 |
| Net cash from operating activities | (349) | 169 | 225 | 134 | 95.01 | 21.38 | 285 |
| Net cash from investing activities | 1,208 | (41.93) | (17.03) | 51.70 | 16.64 | (28.62) | (33.13) |
| Net cash from financing activities | (767) | (128) | (205) | (186) | (119) | 11.49 | (252) |
| Net change in cash | 92.91 | (0.58) | 2.23 | (0.23) | (7.73) | 4.25 | (0.03) |
| Closing cash | 112 | 19.22 | 19.81 | 17.58 | 17.81 | 25.54 | 21.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -100.0% | -0.8% | +10.5% | -8.7% | +8.1% | -34.8% | - |
| EBITDA growth | -902.2% | -119.5% | +185.9% | -66.6% | +89.4% | -61.9% | - |
| PBT growth | -100.2% | - | +9998.0% | - | +9998.0% | - | -36.3% |
| Net income growth | -111.6% | -2430.1% | +107.5% | -457.0% | +137.9% | -251.7% | - |
| Revenue CAGR (3Y) | -100.0% | +0.0% | +3.0% | -13.7% | -15.7% | -6.3% | +12.9% |
| EBITDA CAGR (3Y) | - | - | +21.9% | -37.7% | -15.7% | -29.2% | -0.7% |
| Profitability & leverage | |||||||
| Net income margin | - | -6.8% | +0.3% | -1.6% | +1.5% | -4.8% | +1.3% |
| Return on capital employed | +0.1% | -5.3% | +6.0% | -0.2% | +5.3% | +2.7% | +8.3% |
| Return on net worth | -31.3% | -11.2% | +0.5% | -6.0% | +1.7% | -4.4% | +2.8% |
| Debt / equity | 0.38 | 0.60 | 0.65 | 0.75 | 0.82 | 0.77 | 0.75 |
| Long-term debt / equity | 0.05 | 0.10 | 0.17 | 0.24 | 0.20 | 0.11 | 0.13 |
| Interest cover | -12.18 | -81.11 | 95.94 | -1,300.98 | 77.60 | 477.38 | 79.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 1.17 | 1.22 | 1.12 | 1.23 | 1.15 | 1.76 |
| Inventory turnover | 0.00 | 2.73 | 2.79 | 2.62 | 3.09 | 2.25 | 2.79 |
| Debtors turnover | 0.00 | 5.27 | 5.85 | 4.81 | 4.69 | 4.58 | 5.54 |
| EPS (₹) | (15.08) | (5.07) | 0.22 | (1.08) | 1.12 | (3.27) | 1.42 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Book value per share (₹) | 29.98 | 42.63 | 47.68 | 47.47 | 48.51 | 47.36 | 50.66 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.44 | 1.29 | 0.00 | 5.71 | 5.24 | 0.01 | 455 | 5.74 |
| Revenue growth (YoY) | -91.6% | - | -100.0% | -0.5% | -98.5% | - | - | - |
| Other income | 6.17 | 6.29 | 35.46 | 0.03 | 0.32 | 0.18 | 0.57 | 6.52 |
| Total expenses | 27.68 | 89.23 | 1.92 | 182 | 68.63 | 130 | 410 | 6.32 |
| EBITDA | (27.24) | (87.94) | (1.92) | (176) | (63.39) | (130) | 44.71 | (0.58) |
| EBITDA margin | - | - | - | -3520.2% | -1212.0% | - | +9.8% | -10.1% |
| Depreciation | 0.11 | 0.08 | 0.06 | 0.20 | 0.53 | 0.30 | 15.61 | 0.45 |
| Interest | 0.16 | 5.90 | 30.22 | 0.00 | 0.00 | 0.00 | 17.12 | 0.00 |
| Profit before tax | (21.34) | (87.63) | 3.26 | (176) | (63.60) | (130) | 12.55 | 5.49 |
| Tax | (8.20) | (19.71) | (11.02) | (0.18) | (0.37) | (0.06) | 4.71 | (0.12) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1,684 | 1,524 | 1,668 | 1,542 | 2,363 |
| Revenue growth | - | -100.0% | +10.5% | -8.7% | +8.2% | -34.8% | - |
| Other income | 9.29 | 1.88 | 14.58 | 43.18 | 11.32 | 3.79 | 4.32 |
| Total expenses | 296 | 115 | 1,533 | 1,469 | 1,509 | 1,458 | 2,145 |
| Employee cost | 0.89 | 0.09 | 81.71 | 75.14 | 71.91 | 70.55 | 78.19 |
| EBITDA | (296) | (115) | 152 | 54.73 | 159 | 83.82 | 218 |
| EBITDA margin | - | - | +9.0% | +3.6% | +9.5% | +5.4% | +9.2% |
| Depreciation | 0.34 | 0.62 | 60.72 | 59.12 | 56.97 | 60.25 | 60.77 |
| Interest | 36.13 | 0.00 | 87.14 | 79.48 | 78.81 | 112 | 126 |
| Profit before tax | (323) | (113) | 18.28 | (40.69) | 34.35 | (84.67) | 35.75 |
| Tax | (30.53) | 0.38 | 13.27 | (18.24) | 9.03 | (11.50) | 5.68 |
| Net profit | (241) | (114) | 4.83 | (62.96) | 15.91 | (47.76) | 29.85 |
| Net profit margin | - | - | +0.3% | -4.1% | +1.0% | -3.1% | +1.3% |
| EPS (₹) | (15.08) | (5.07) | 0.22 | (1.00) | 1.13 | (3.26) | 1.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 19.43 | 22.43 | 22.43 | 22.43 | 22.43 | 22.43 | 22.43 |
| Reserves & surplus | 563 | 934 | 1,047 | 1,042 | 1,064 | 1,038 | 1,112 |
| Shareholders' funds (net worth) | 582 | 956 | 1,069 | 1,065 | 1,087 | 1,061 | 1,135 |
| Secured loans | 0.00 | 487 | 540 | 672 | 784 | 825 | 760 |
| Unsecured loans | 0.00 | 94.68 | 96.01 | 81.44 | 76.08 | 77.99 | 18.45 |
| Total debt | 0.00 | 582 | 636 | 754 | 860 | 903 | 779 |
| Total liabilities | 586 | 1,548 | 1,713 | 1,826 | 1,955 | 1,975 | 1,925 |
| Assets | |||||||
| Gross block | 5.91 | 1,652 | 1,599 | 1,558 | 1,563 | 1,556 | 1,509 |
| Net block | 3.45 | 633 | 643 | 662 | 723 | 772 | 785 |
| Capital work in progress | 0.00 | 56.73 | 65.75 | 77.78 | 85.10 | 98.63 | 115 |
| Investments | 13.46 | 0.77 | 0.74 | 0.56 | 1.03 | 1.03 | 0.74 |
| Inventories | 0.30 | 690 | 709 | 673 | 660 | 587 | 975 |
| Sundry debtors | 0.00 | 345 | 379 | 280 | 447 | 375 | 397 |
| Cash & bank balances | 108 | 19.22 | 19.80 | 17.57 | 17.74 | 25.43 | 21.23 |
| Loans & advances | 128 | 182 | 175 | 261 | 229 | 250 | 220 |
| Total current assets | 237 | 1,237 | 1,283 | 1,231 | 1,353 | 1,237 | 1,614 |
| Total current liabilities | 25.97 | 500 | 478 | 364 | 435 | 412 | 591 |
| Net working capital | 211 | 737 | 806 | 867 | 918 | 825 | 1,023 |
| Total assets | 586 | 1,548 | 1,713 | 1,826 | 1,955 | 1,975 | 1,925 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 19.22 | 19.80 | 17.57 | 17.74 | 25.43 | 21.23 | 20.58 |
| Net cash from operating activities | (417) | 169 | 225 | 133 | 95.04 | 21.33 | 286 |
| Net cash from investing activities | 1,205 | (41.93) | (17.03) | 52.03 | 16.64 | (28.62) | (33.14) |
| Net cash from financing activities | (699) | (128) | (205) | (186) | (119) | 11.49 | (252) |
| Net change in cash | 88.91 | (0.58) | 2.23 | (0.17) | (7.70) | 4.20 | 0.65 |
| Closing cash | 108 | 19.22 | 19.80 | 17.57 | 17.74 | 25.43 | 21.23 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | - | -100.0% | +10.5% | -8.7% | +8.2% | -34.8% | - |
| EBITDA growth | -158.6% | -175.6% | +176.9% | -65.5% | +89.5% | -61.6% | - |
| PBT growth | -185.4% | - | +9998.0% | - | +9998.0% | - | -39.0% |
| Net income growth | -111.6% | -2454.7% | +107.7% | -495.7% | +133.3% | -260.0% | - |
| Revenue CAGR (3Y) | -100.0% | -100.0% | +3.0% | -13.6% | -15.7% | -6.3% | +12.9% |
| EBITDA CAGR (3Y) | - | - | +21.8% | -36.9% | -15.6% | -29.2% | -0.9% |
| Profitability & leverage | |||||||
| Net income margin | - | - | +0.3% | -1.5% | +1.5% | -4.8% | +1.3% |
| Return on capital employed | +0.1% | +0.1% | +6.0% | -0.1% | +5.3% | +2.7% | +8.2% |
| Return on net worth | -31.3% | -11.2% | +0.5% | -5.9% | +1.5% | -4.4% | +2.7% |
| Debt / equity | 0.38 | 0.60 | 0.65 | 0.75 | 0.82 | 0.77 | 0.75 |
| Long-term debt / equity | 0.04 | 0.10 | 0.17 | 0.24 | 0.20 | 0.11 | 0.13 |
| Interest cover | -12.18 | 0.00 | 95.93 | -1,810.48 | 77.39 | 475.31 | 80.01 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 1.22 | 1.12 | 1.23 | 1.15 | 1.76 |
| Inventory turnover | 0.00 | 0.00 | 2.79 | 2.62 | 3.09 | 2.26 | 2.79 |
| Debtors turnover | 0.00 | 0.00 | 5.85 | 4.81 | 4.69 | 4.57 | 5.51 |
| EPS (₹) | (15.08) | (5.07) | 0.22 | (1.00) | 1.13 | (3.26) | 1.34 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Book value per share (₹) | 29.98 | 42.63 | 47.68 | 47.47 | 48.46 | 47.30 | 50.59 |
To see the full year-wise statements and ratios of Nectar Life Sciences Limited, buy the company report.
Board of directors of Nectar Life Sciences Limited
Nectar Life Sciences has 6 current directors and 26 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Indu Pal Kaur Also directs: Hernovis LLP, Casanova R&D Private Limited | Director | 02 Aug 2022 | 4 Years 2 Months | Current |
| Rupinder Tewari Also directs: Nureca Limited | Director | 11 Feb 2019 | 7 Years 8 Months | Current |
| Kuldip Kumar Bhasin Also directs: Nureca Limited | Director | 21 Sep 2021 | 5 Years 1 Months | Current |
| Sushil Kapoor | Whole-Time Director | 04 Dec 2025 | 0 Years 10 Months | Current |
| Sanjiv Goyal Also directs: Nectar Organics Private Limited | Managing Director | 27 Jun 1995 | 31 Years 4 Months | Current |
| Surulichamy Senthilkumar | Director | 10 Nov 2025 | 0 Years 11 Months | Current |
Peer comparison
Nectar Life Sciences Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Leeford Healthcare Limited | ₹1,730.47 Cr (FY 2025) | 5.0% | Ludhiana, Punjab, India | |||
| MSN Pharmachem Private Limited | ₹1,716.51 Cr (FY 2024) | 40.0% | Hyderabad, Telangana, India | |||
| Bharat Biotech International Limited | ₹1,699.59 Cr (FY 2025) | 4.0% | Hyderabad, Telangana, India | |||
| Camlin Fine Sciences Limited | ₹1,680.98 Cr (FY 2025) | 14.0% | Mumbai, Maharashtra, India | |||
| Payal Polyplast Private Limited | ₹1,679.14 Cr (FY 2025) | 0.0% | New Delhi, Delhi, India | |||
| Sri Ramana Solvex Private Limited | ₹1,671.54 Cr (FY 2025) | -43.0% | Mahaboobnagar, Telangana, India | |||
| Indoco Remedies Limited | ₹1,670.37 Cr (FY 2025) | -9.0% | Mumbai, Maharashtra, India | |||
| Jay Chemical Industries Private Limited | ₹1,670.11 Cr (FY 2025) | 19.0% | Ahmedabad, Gujarat, India | |||
| Panoli Intermediates (India) Private Limited | ₹1,643.14 Cr (FY 2025) | 29.0% | New Delhi, Delhi, India | |||
| Silox India Private Limited | ₹1,629.82 Cr (FY 2025) | 6.0% | Vadodara, Gujarat, India |
To see the full peer comparison of Nectar Life Sciences Limited, buy the company report.
Auditor
Nectar Life Sciences Limited is audited by DEEPAK JINDAL & CO. for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DEEPAK JINDAL & CO. | FY 2025 | 023023N |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 51.80%, foreign institutional investors hold 0.50%, domestic institutional investors hold 3.80% and retail and other public shareholders hold 43.90%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 51.80% | 51.80% | 44.90% | 44.90% |
| Public | 48.20% | 48.20% | 55.10% | 55.10% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Dec 2023 | 100841946 | Hdfc Bank Limited | ₹60.47 Lakh | Satisfied | |
| 28 Jun 2022 | 100593892 | Hdfc Bank Limited | ₹20 Lakh | Satisfied | |
| 01 Dec 2021 | 100511693 | Hdfc Bank Limited | ₹20 Lakh | Satisfied | |
| 14 Jul 2021 | 100465635 | Hdfc Bank Limited | ₹6 Lakh | Satisfied | |
| 21 Jun 2021 | 100458233 | Sbicap Trustee Company Limited | ₹1,338.35 Cr | Satisfied |
To see the full charge records of Nectar Life Sciences Limited, buy the company report.
Total charge records: 111 View all charges
Deals & funding
Nectar Life Sciences Limited has 66 deals on record (61 market trades, 3 funding rounds, 1 secondary share transfer), with disclosed funding of ₹201.41 Cr; the latest was in December 2025.
Deals on record (5 of 66)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2025 | Market trade | ₹13.18 Cr | Buyer: Marwadi Chandarana Intermediaries Brokers Private Limited , Rajasthan Global Securities Private Limited , Qe Securities LLP , an individual Seller: Irage Broking Services LLP , Qe Securities LLP , 2 individuals |
| Jul 2025 | Market trade | ₹6.4 Cr | Buyer: Share India Securities Limited, L7 Hitech Private Limited Seller: L7 Hitech Private Limited , Share India Securities Limited |
| Jul 2025 | Market trade | ₹6.8 Cr | Buyer: Share India Securities Limited, Hrti Private Limited Seller: Share India Securities Limited, Hrti Private Limited |
| Jul 2025 | Market trade | ₹7.96 Cr | Buyer: Share India Securities Limited, L7 Hitech Private Limited , Hrti Private Limited Seller: Share India Securities Limited, Hrti Private Limited |
| Jul 2025 | Market trade | ₹15.61 Cr | Buyer: Mansi Share and Stock Broking Private Limited , Share India Securities Limited Seller: Mansi Share and Stock Broking Private Limited , Tradelink Investments, Quarks Technosoft Private Limited |
To see the full deal history of Nectar Life Sciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Nectar Life Sciences Limited has 436 court cases on record: 347 filed by Nectar Life Sciences, 89 filed against it. 34 cases are pending and 402 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 321 | 33 | 16 |
| High courts | 97 | 45 | 14 |
| Supreme Court | 18 | 11 | 4 |
Cases on record (5 of 436)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Chandigarh | Cheque dishonour complaint | Filed by the company against Nupur Pharma Private Limited | Pending |
| High Court of Punjab and Haryana | Writ petition | Filed against the company by New India Assurance Company Limited and 1 other | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Court case (Cri.Appeal) | Filed by the company against Manav Drugs Pvt Ltd and 5 Ors ( 63Rd Court at Andheri) | Pending |
| Supreme Court | Appeal | Filed against the company by National Stock Exchange of India Limited | Pending |
| District court, Chandigarh | Execution petition | Filed against the company by Abb India Ltd | Pending |
To see the full case history of Nectar Life Sciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Nectar Life Sciences Limited was last rated by Brickwork on 15 Jul 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Brickwork | 15 Jul 2021 |
To see the full credit ratings and regulatory alerts of Nectar Life Sciences Limited, buy the company report.
MSME payment delays
Nectar Life Sciences Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 185 overdue payments to 21 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 21)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Zealand Aviation Private Limited | |||
| Freudenberg Filtration Technologies India Private Limited | |||
| Shree Nath Life Sciences Private Limited | |||
| Ferguson Chemicals | |||
| Aardour Worldwide Logistics Private Limited |
To see the full MSME payment records of Nectar Life Sciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Nectar Life Sciences Limited has a workforce of 1,814 employees on its EPFO records as of Nov 28, 2025, across 4 active EPFO establishments.
GST
Nectar Life Sciences has 18 GST registrations: 5 active and 13 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 03AABCS6468G1ZD | Punjab | Active | 01 Jul 2017 |
| 02AABCS6468G1ZF | Himachal Pradesh | Active | 01 Jul 2017 |
| 01AABCS6468G2ZG | Jammu and Kashmir | Active | 08 Jul 2017 |
| 04AABCS6468G3Z9 | Chandigarh | Active | 16 Jul 2017 |
To see the full GST registrations and return filing status of Nectar Life Sciences Limited, buy the company report.
Recent activity
Nectar Life Sciences Limited has 48 board changes on record since 1995: 27 appointments and 21 cessations. The latest: Sushil Kapoor was appointed as Whole-Time Director on 04 Dec 2025.
298 earlier events are in the company report.
News
Frequently asked questions
Nectar Life Sciences is an active public limited company based in Derabassi, Punjab, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 27 June 1995 (31+ years old) and is registered under CIN L24232PB1995PLC016664. Listed on BSE: 532649 and NSE: NECLIFE.
Nectar Life Sciences has 6 current directors:
- Sanjiv Goyal - Managing Director
- Sushil Kapoor - Whole-Time Director
- Indu Pal Kaur - Director
- Rupinder Tewari - Director
- Kuldip Kumar Bhasin - Director
- Surulichamy Senthilkumar - Director
The latest financial statements of Nectar Life Sciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Nectar Life Sciences is 03AABCS6468G1ZD, registered in Punjab. The company has 18 GST registrations in all, of which 5 are active and 13 are cancelled or inactive. Other active GSTINs include 02AABCS6468G1ZF (Himachal Pradesh), 01AABCS6468G2ZG (Jammu and Kashmir), 04AABCS6468G3Z9 (Chandigarh).
The CIN (Corporate Identification Number) of Nectar Life Sciences is L24232PB1995PLC016664. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Nectar Life Sciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 532649) and NSE (symbol: NECLIFE).
Nectar Life Sciences has 436 court cases on record: 347 filed by the company and 89 filed against it. 34 are pending. Most are in the district courts.
Nectar Life Sciences was incorporated on 27 June 1995, making it 31+ years old. It is registered with the Registrar of Companies, Chandigarh.
Nectar Life Sciences has 66 deals on record (61 market trades, 3 funding rounds, 1 secondary share transfer), with disclosed funding of ₹201.41 Cr; the latest was in December 2025.
The peers of Nectar Life Sciences by revenue are Leeford Healthcare Limited, MSN Pharmachem Private Limited, Bharat Biotech International Limited, Camlin Fine Sciences Limited, Payal Polyplast Private Limited and 5 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Sushil Kapoor was appointed as Whole-Time Director on 04 Dec 2025. Surulichamy Senthilkumar was appointed as Director on 10 Nov 2025. Meena Virbhan Verma ceased to be Nominee Director on 27 Oct 2025. Nectar Life Sciences has 48 board changes on record in total.
Nectar Life Sciences has 12 MSME Form 1 returns on record between 2019 and 2024, listing 185 overdue payments to 21 micro and small suppliers. The latest return was filed on 30 Apr 2024.